Cellectis S.A. (CLLS) vs Cumberland Pharmaceuticals (CPIX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Cumberland Pharmaceuticals (CPIX) has outperformed Cellectis S.A. (CLLS) over the past year, gaining 108.7% versus a loss of 73.9%. Over five years, CPIX leads with a +167.9% price change compared with -90.3% for CLLS. Cumberland Pharmaceuticals is the larger company by market cap ($107.6 million vs $104.8 million), about 1.0 times the size, while Cellectis S.A. is growing revenue faster (+75.8% vs +17.6%).
Cumberland Pharmaceuticals converts more of its revenue into profit, with a net margin of -6.4% versus -92.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLLS | CPIX |
|---|---|---|
| Share price | $1.04 | $7.18 |
| Market cap | $104.76M | $107.58M |
| 1-day change | -5.88% | -4.77% |
| YTD return | -78.51% | +80.40% |
| 1-year return | -73.87% | +108.72% |
| 5-year return | -90.34% | +167.91% |
| Forward P/E | — | 51.29 |
| EPS (TTM) | $-0.64 | $-0.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $72.95M | $44.52M |
| Revenue growth (YoY) | +75.76% | +17.57% |
| Net income (latest FY) | $-67.59M | $-2.84M |
| Gross margin | 100.00% | 85.02% |
| Operating margin | -45.34% | -6.27% |
| Net margin | -92.66% | -6.37% |
| 52-week high | $5.45 | $9.28 |
| 52-week low | $1.03 | $1.85 |
| Distance from 52-week high | -80.92% | -22.63% |
| Analyst consensus | none | — |
| Avg. price target upside | +364.42% | — |
| Average volume | 86.69K | 76.95K |
| Shares outstanding | 72.73M | 14.98M |
| Employees | 224 | 88 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CPIX has outperformed CLLS by 182.6 percentage points over the past year.
- Cumberland Pharmaceuticals is more profitable, keeping -6.4 cents of every revenue dollar as net income versus -92.7 cents for Cellectis S.A..
- Cellectis S.A. grew revenue faster in its latest fiscal year (+75.76% vs +17.57%).
About Cellectis S.A.
CLLS stock →Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL).
Health Care · Biotechnology: Pharmaceutical Preparations · 224 employees
About Cumberland Pharmaceuticals
CPIX stock →Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Tacilia, an oral capsule for the treatment of H.
Health Care · Biotechnology: Pharmaceutical Preparations · 88 employees
CLLS vs CPIX FAQ
Which is bigger, Cellectis S.A. or Cumberland Pharmaceuticals?
Cumberland Pharmaceuticals (CPIX) is larger, with a market capitalization of $107.58M compared with $104.76M for Cellectis S.A. (CLLS).
Which stock has performed better over the past year, CLLS or CPIX?
CPIX returned +108.72% over the past 12 months, compared with -73.87% for CLLS (price return, excluding dividends). Past performance does not predict future results.
Are Cellectis S.A. and Cumberland Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.